Clinical Trials on Inclusion Body Myopathy, Autosomal-dominant in Japan

Total 22 results

Nobelpharma

Completed

Efficacy Confirmation Study of NPC-09

GNE Myopathy | Nonaka Disease | Distal Myopathy With Rimmed Vacuoles (DMRV) | Hereditary Inclusion Body Myopathy (hIBM)

Japan
Kyorin University

Unknown

Efficacy of Tolvaptan on ADPKD Patients

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Autosomal Dominant Polycystic Kidney Disease

Japan
Kyorin University
Otsuka Pharmaceutical Co., Ltd.

Completed

Clinical Implications of DNA Analysis on ADPKD (DNAAA)

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Autosomal Dominant Polycystic Kidney Disease

Japan
Tohoku University

Completed

Pharmacokinetic Study on N-acetylneuraminic Acid

Hereditary Inclusion Body Myopathy | Nonaka Myopathy

Japan
Kyorin University
Ministry of Health, Labour and Welfare, Japan

Unknown

CCB Safety Study in Treatment of Hypertension of ADPKD

Kidney, Polycystic, Autosomal Dominant

Japan
Kyorin University

Completed

Efficacy Study of Water Drinking on PKD Progression. (ESWP)

Disease Progression | Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
Ministry of Health, Labour and Welfare, Japan

Unknown

Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

Kidney, Polycystic, Autosomal Dominant

Japan
Rege Nephro Co., Ltd.

Recruiting

Study of Tamibarotene in Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

Polycystic Kidney, Autosomal Dominant

Japan
Sanofi

Terminated

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat (STAGED-PKD-EXT)

Congenital Cystic Kidney Disease

Germany, Spain, United States, Australia, Belgium, Japan, Korea, Republic of, Netherlands
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease (OVERTURE)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Italy, Japan, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Genzyme, a Sanofi Company

Terminated

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (STAGED-PKD)

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Czechia, United States, Italy, Poland, Argentina, Australia, Austria, Canada, China, Denmark, France, Israel, Japan, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Taiwan, Turkey, United Kingdom
Reata, a wholly owned subsidiary of Biogen

Terminated

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON)

Autosomal Dominant Polycystic Kidney | ADPKD

United States, Spain, United Kingdom, Australia, France, Japan, Germany, Belgium, Czechia, Italy
Calcilytix Therapeutics, Inc., a BridgeBio company

Recruiting

ADH1 and ADH2 Disease Monitoring Study (DMS) (CLARIFY)

Autosomal Dominant Hypocalcemia

United States, France, Denmark, Australia, Japan, Belgium, Canada, Italy, Netherlands, United Kingdom, Portugal, Finland, Germany
Calcilytix Therapeutics, Inc., a BridgeBio company

Recruiting

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (CALIBRATE)

Autosomal Dominant Hypocalcemia (ADH)

United States, Australia, United Kingdom, Denmark, Italy, France, Japan, Taiwan, Canada, Czechia, Netherlands
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients (RESILIENT)

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Novartis Pharmaceuticals

Completed

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Reata, a wholly owned subsidiary of Biogen

Terminated

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE)

Chronic Kidney Diseases | Autosomal Dominant Polycystic Kidney | Alport Syndrome

United States, France, Australia, Japan, Spain, Puerto Rico

Clinical Trials on Inclusion Body Myopathy, Autosomal-dominant in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations